Luminex Corporation was incorporated in May 1995 and began commercial production of the first generation system in 1997. Luminex® (NASDAQ: LMNX) develops, manufactures and markets innovative biological testing technologies with applications throughout the life science and diagnostic industries. The Company’s open-architecture xMAP® Technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately. Systems using xMAP Technology perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. Using lasers and high-speed digital-signal processors, the analyzer simultaneously identifies the bioassay and measures the results, all in real time.
Luminex Vision Statement: Breakthrough solutions to improve health and advance science.

Type
Public
HQ
Austin, US
Employees
797 (est)
Luminex is headquartered in Austin, US

Luminex Locations

Austin, US
Shanghai, CN
Madison, US
's-Hertogenbosch, NL
Toronto, CA
Minato-ku, JP

Luminex Metrics

Luminex Summary

Market capitalization

$880 M

Closing share price

$20.7
Luminex's current market capitalization is $880 M.

Luminex Financials

Luminex's revenue is $238 M in FY, 2015 which is 4.73% increase from the previous period.
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Revenue

$10.7 M$227 M$238 M

Gross profit

$144 M$160 M$169 M

Operating income

$4.77 M$28.1 M$37.4 M

Operating expense total

$139 M$132 M$131 M

Income tax expense

$6.12 M$9.46 M$10.4 M

Net Income

$7.1 M$39 M$36.9 M

Operating cash flow

$25.1 M$23.8 M$36.9 M

    Luminex Market Value History

    Luminex Online Presence

    Luminex Company Life

    You may also be interested in